Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. August 2018 14:00 ET | Quelle: Exonics Therapeutics

Exonics Announces Publication of Research Demonstrating Gene Repair Technology Restored Dystrophin Expression in Canine Model of Duchenne Muscular Dystrophy

Systemic delivery of SingleCut CRISPR gene editing components restored dystrophin expression to up to 92 percent of normal expression in heart muscle in canines First study of Exonics’ SingleCut...
30. Januar 2018 08:00 ET | Quelle: Exonics Therapeutics

Exonics Therapeutics Appoints Roger M. Perlmutter, M.D., Ph.D., to Board of Directors

CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne...
08. November 2017 07:30 ET | Quelle: Exonics Therapeutics

Exonics Therapeutics Raises $40 Million in Series A Financing

CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne...
27. Februar 2017 07:30 ET | Quelle: Exonics Therapeutics

Exonics Therapeutics Launches with Funding from CureDuchenne Ventures to Advance CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy

BOSTON, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to permanently correct a...